Maik W. Jornitz Becomes Chair-Elect of the Board of the Global Parenteral Drug Association

  
    
  
  
    
      After yesterday’s meeting, the Board of 
      Directors announced the election of Maik W. Jornitz as Chair-Elect (Vice 
      Chairman) of the Board of the Parenteral Drug Association (PDA). The 
      Group Vice President, Marketing Filtration and Fermentation, at 
      Sartorius Stedim Biotech (FWB:SRT), has been an active member of the PDA 
      for close to 15 years, holding multiple functions. Before becoming 
      Chair-Elect, he was Treasurer and Chair of the 2008 Annual Meeting as 
      well as a Task Forces member, including his direct involvement in 
      Technical Report 26 on Liquid Sterilizing Filtration. The PDA is a key 
      global pharmaceutical association with over 10,000 members.
    
    
      “The PDA is the most prominent and effective 
      platform of scientific communication and discussion between members of 
      the biopharmaceutical and pharmaceutical industry, academia and 
      regulatory institutions,” said Jornitz. “It 
      is an honor to be part of PDA’s vital function 
      in supporting regulators and the biopharmaceutical industry as well as 
      shaping the newest developments in this industry. I am very happy to 
      join this senior level and distinguished Board of Directors.” 
      John Shabushnig was elected Chair of the PDA Board. Furthermore, 
      representatives of the pharmaceutical groups Genentech, Amgen, Pfizer, 
      Baxter and Eli Lilly, among others, belong to this Board.
    
    
      Maik W. Jornitz has been with Sartorius for over 20 years and is an 
      established filtration technology expert with a focus on sterilizing 
      filtration, process validation and integrity testing. Jornitz authored 
      and co-authored numerous scientific books, and regularly publishes 
      technical papers. He holds multiple patents for integrity test methods 
      and filter housing designs. Jornitz is a faculty member of PDA’s 
      Training & Research Institute.
    
    
      Current image file:
    
    
      Maik W. Jornitz, Group Vice President Marketing & Product Management 
      Filtration/Fermentation Technologies at Sartorius Stedim Biotech.
    
    
      http://www.sartorius-stedim.com/media/content/press/support/Jornit 
      z.jpg
    
    
      (Due to its length, this URL may need to be copied/pasted into your 
      Internet browser's address field. Remove the extra space if one exists.)
    
    
      A profile of Sartorius Stedim Biotech
    
    
      Sartorius Stedim Biotech is a leading provider of cutting-edge equipment 
      and services for the development, quality assurance and production 
      processes of the biopharmaceutical industry. Its integrated solutions 
      covering fermentation, filtration, purification, fluid management and 
      lab technologies are supporting the biopharmaceutical industry around 
      the world to develop and produce drugs safely, timely and economically. 
      For next generation processes, Sartorius Stedim Biotech focuses on 
      single-use technologies and added-value services to meet the rapidly 
      changing technology requirements of the industry it serves. Strongly 
      rooted in the scientific community and closely allied with customers and 
      technology partners, the company is dedicated to its philosophy of “Turning 
      science into solutions.”
    
    
      Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on 
      the Eurolist of Euronext Paris. With its own manufacturing and sales 
      companies in Europe, North America and Asia, Sartorius Stedim Biotech 
      enjoys a worldwide presence. Its key manufacturing and R&D location is 
      in Germany. The company employs over 2,200 people, and in 2006 earned 
      pro forma sales revenue of more than 360 million euros.
    
    
      This is a translation of the original German-language press release. 
      Sartorius shall not assume any liability for the correctness of this 
      translation. The original German press release is the legally binding 
      version. Furthermore, Sartorius reserves the right not to be responsible 
      for the topicality, correctness, completeness or quality of the 
      information provided. Liability claims regarding damage caused by the 
      use of any information provided, including any kind of information which 
      is incomplete or incorrect, will therefore be rejected.
    
    
      http://www.sartorius-stedim.com